MBOT
NASDAQMicrobot Medical Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$1.96-0.03 (-1.51%)
01:30 PM07:45 PM
News · 26 weeks570%
2025-12-072026-05-31
Mix3690d
- SEC Filings16(44%)
- Other11(31%)
- Insider6(17%)
- Leadership2(6%)
- Earnings1(3%)
Latest news
25 items- SECMicrobot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)
- PRMicrobot Medical® Secures the First Healthcare System in North Carolina to Adopt the LIBERTY® Endovascular Robotic SystemHINGHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has secured its first North Carolina-based customer, becoming the latest healthcare system to adopt the LIBERTY System, demonstrating a broadening geographic penetration from the Southeast, Mid-Atlantic and Northeast U.S. The Company's latest account delivers state of the art patient care through a multi-hospital network that encompasses the entire state and joins a growing roster of health systems that we believe recognize the unique benefits of the LIBERTY system. "It's exciting to see the pace of incre
- PRMicrobot Medical® Receives Its First International Regulatory Approval for the Commercialization of the LIBERTY® Endovascular Robotic SystemIsrael becomes the second jurisdiction and the first outside of the U.S. to grant marketing clearance for the LIBERTY System The AMAR regulatory approval will enable the Company to obtain a Free Sale Certificate to support submissions and commercial activities in additional jurisdictions HINGHAM, Mass.,, May 26, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has achieved a significant regulatory milestone as Israel becomes the second jurisdiction — and the first outside of the U.S. — to grant marketing clearance for the LIBERTY System. The regulatory approval from the Israe
- SECMicrobot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)
- SECMicrobot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)
- PRMicrobot Medical to Hold Analysts and Investors Conference Call to Review Recent Progress; Executive Team will be Joined by Current Users of the LIBERTY Endovascular Robotic System, Dr. Charles Briggs and Dr. Zachary BercuConference call and live webcast to be held Monday, May 18th at 3:00pm ET Wall Street firm publishes research report refuting claims made by recent unaffiliated third-party article; Research report also references Vascular Surgeon who categorically disputes many of the assertions that were attributed to him in same unaffiliated third-party article Company to review claims made in the unaffiliated third-party article, to correct certain misleading statements and misrepresentations to ensure the investing public is fully informed of the actual facts HINGHAM, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® E
- SECMicrobot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)
- PRMicrobot Medical Successfully Transitions to Commercial Operations as It Records Revenue Resulting from Its Limited Market Release During the First Quarter of 2026Recent transition to the Full Market Release has already resulted in increased revenue for the current Q2, which has already exceeded Q1 revenue, as utilization and adoption of the LIBERTY System accelerates across multiple sales territories Company experiencing increase in recurring customer orders, new accounts and growing pipeline of potential future accounts HINGHAM, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it recorded revenue during its fiscal quarter ended March 31, 2026, benefiting from the Limited Market Release (LMR) of the LIBERTY System which to
- SECSEC Form 10-Q filed by Microbot Medical Inc.10-Q - Microbot Medical Inc. (0000883975) (Filer)
- SECMicrobot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)
- PRMicrobot Medical®'s LIBERTY® Endovascular Robotic System is Now Adopted by Multiple Accounts Across Key Territories Including Two ACCESS-PVI Pivotal Clinical Trial SitesCommercial adoption of the LIBERTY System by sites that participated in the clinical trial serves as a strong validation of the value it brings to everyday practice The Company will attend the Annual Global Embolization Symposium & Technologies (GEST), a Premier Medical Conference in New York City that attracts over 1,000 global experts across key target call points HINGHAM, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY Endovascular Robotic System, which is experiencing strong interest from physicians and hospital executives following the commencement of the Full Market Release of LIBERTY at the recent Soc
- PRMicrobot Medical® Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in Europe, the Middle East, and Asia (EMEA)Commencement of activities in international markets is supported by the successful completion of the Limited Market Release, followed by the Recent Full Market Release in the U.S. Strong physician interest at recent Society of Interventional Radiology conference and rising awareness across markets outside the U.S. supports commercial readiness throughout heavily populated regions HINGHAM, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY Endovascular Robotic System, is continuing to implement its growth strategy with the appointment of Alon Tamir as Vice President of Sales, Europe, the Middle East and Asia
- SECMicrobot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)
- PRMicrobot Medical® Welcomes Updated Occupational Protection Guidelines from Leading Medical Societies, Strengthening Commercial Position of LIBERTY®Members of the Society of Interventional Radiology (SIR) and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Represent the Largest Addressable User Market for the LIBERTY System At least Nine Medical Societies Endorse Updated Guidelines to Lower Radiation Exposure and Improve Ergonomic Issues Impacting Health Practitioners HINGHAM, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, today highlighted that the Society of Interventional Radiology (SIR) and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), recently released up
- PRMicrobot Medical® to Highlight Commercial Achievements Leading to the Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare ConferenceHINGHAM, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it will highlight recent commercial achievements leading to the recent Full Market Release (FMR) of the LIBERTY System at the 25th Annual Needham Virtual Healthcare Conference, being held April 13-16th. Harel Gadot, CEO, President & Chairman of Microbot Medical, will be presenting live at 10:15 a.m. ET on Wednesday, April 15, 2026. Mr. Gadot, along with other of Microbot's senior executives, will provide an overview of the Company and its strategic positioning, growth opportunities, and ability to address ma
- SECMicrobot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)
- SECMicrobot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)
- PRMicrobot Medical® Commences Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System in the U.S. at the Society of Interventional Radiology (SIR) Annual Scientific MeetingHINGHAM, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced today that it has successfully executed its limited market release (LMR) and will commence its full market release (FMR) in the U.S. as planned. To date, LIBERTY has been adopted by multiple healthcare systems with dozens of hospitals in their networks, including globally recognized hospitals such as Emory Healthcare and Tampa General Hospital. Microbot considers this achievement a reflection of the highly effective execution of the LIBERTY System's LMR and positions the Company to commence the FMR of the LIBERTY
- SECSEC Form 424B5 filed by Microbot Medical Inc.424B5 - Microbot Medical Inc. (0000883975) (Filer)
- SECMicrobot Medical Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)
- INSIDERSEC Form 4 filed by Madden Martin J.4 - Microbot Medical Inc. (0000883975) (Issuer)
- INSIDERSEC Form 4 filed by Stockburger Aileen Ptucha4 - Microbot Medical Inc. (0000883975) (Issuer)
- INSIDERSEC Form 4 filed by Wenderow Tal Baruch4 - Microbot Medical Inc. (0000883975) (Issuer)
- INSIDERSEC Form 4 filed by Wilson David James4 - Microbot Medical Inc. (0000883975) (Issuer)
- INSIDERSEC Form 4 filed by Burell Scott R4 - Microbot Medical Inc. (0000883975) (Issuer)
MBOT FAQ
6 questionsWhat does Microbot Medical Inc. do?
Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable self-propelled locomotive device to treat capabilities within tubular lumens, such as the blood vessels, respiratory, and the urinary and GI tracts; a combination of a guidewire and microcatheter technologies that...Where does MBOT stock trade?
Microbot Medical Inc. (MBOT) is listed on NASDAQ.What sector and industry is MBOT in?
Microbot Medical Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about MBOT?
Microbot Medical Inc. has had 2 recent analyst actions on file. The most recent action was from B. Riley Securities: Buy with a $500.00 price target on 2026-02-10. Recent price targets range from $500.00 to $550.00.What companies are similar to MBOT?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare MBOT side-by-side with any of them on Quantisnow.How can I track MBOT on Quantisnow?
Quantisnow aggregates Microbot Medical Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MBOT to receive live email and push alerts on every new disclosure.